COMPASS Pathways’ (CMPS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock.

Several other research analysts have also issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Canaccord Genuity Group decreased their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Stifel Nicolaus assumed coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Stock Down 0.5 %

Shares of NASDAQ CMPS opened at $4.02 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company has a 50-day moving average price of $4.05 and a 200-day moving average price of $5.17. The stock has a market capitalization of $275.05 million, a P/E ratio of -1.83 and a beta of 2.29. COMPASS Pathways has a 1 year low of $3.17 and a 1 year high of $11.72.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities research analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth $41,000. Flagship Harbor Advisors LLC purchased a new position in COMPASS Pathways during the 4th quarter worth $43,000. Wealthfront Advisers LLC acquired a new position in COMPASS Pathways during the 4th quarter valued at about $43,000. Conservest Capital Advisors Inc. raised its stake in COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in COMPASS Pathways in the fourth quarter worth about $54,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.